Literature DB >> 25266116

Should patient groups be more transparent about their funding?

Sophie Arie, Chris Mahony.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25266116     DOI： 10.1136/bmj.g5892

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Direct-to-consumer Marketing to People with Hemophilia.

Authors:  Philip Kucab; Katelyn Dow Stepanyan; Adriane Fugh-Berman
Journal:  PLoS Med       Date:  2016-06-14       Impact factor: 11.069

2.  National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study.

Authors:  Joel Lexchin; Sharon Batt; Devorah Goldberg; Adrienne Shnier
Journal:  BMJ Open       Date:  2022-03-09       Impact factor: 2.692

3.  Patients not patents: Drug research and development as a public enterprise.

Authors:  Peter C Gøtzsche
Journal:  Eur J Clin Invest       Date:  2018-01-05       Impact factor: 4.686

4.  "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.

Authors:  Lisa Parker; Alice Fabbri; Quinn Grundy; Barbara Mintzes; Lisa Bero
Journal:  BMJ       Date:  2019-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.